Suwon, South Korea

Jee Hun Yun

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: C&c Research Laboratories. Active years: 2020.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jee Hun Yun

Introduction

Jee Hun Yun is a notable inventor based in Suwon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic derivatives. His work focuses on compounds that have therapeutic potential in treating diseases linked to the activation of specific proteins.

Latest Patents

Jee Hun Yun holds a patent for "Heterocyclic derivatives and use thereof." This patent describes a heterocyclic derivative represented by a specific formula, which exhibits an inhibitory effect on the activation of the STAT3 protein. This compound is valuable for the prevention or treatment of diseases associated with the activation of STAT3 protein. He has 1 patent to his name.

Career Highlights

Jee Hun Yun is currently employed at C&C Research Laboratories, where he continues to innovate and develop new pharmaceutical solutions. His work is characterized by a commitment to advancing medical science and improving patient outcomes.

Collaborations

Throughout his career, Jee Hun Yun has collaborated with talented individuals such as Chan Hee Park and Jungsook Kim. These partnerships have contributed to the success of his research and the development of new therapeutic agents.

Conclusion

Jee Hun Yun is a dedicated inventor whose work in heterocyclic derivatives has the potential to impact the treatment of various diseases. His contributions to the field of pharmaceuticals highlight the importance of innovation in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…